Drug Trial Radar · NCT02867813
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Last checked: Nov 20, 2026Latest source record: Apr 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,035
Actual
Start
Sep 2, 2016
Primary completion
Mar 21, 2022
Study completion Mar 21, 2022
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).
Conditions
- Dyslipidemia
Interventions
EvolocumabBiological
subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced an Adverse EventTime frame: Up to 5 years
Locations
198 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Huntsville, Alabama
Research Site
Phoenix, Arizona
Research Site
Banning, California
Research Site
Long Beach, California
Research Site
Oceanside, California
Research Site
Oxnard, California
Research Site
Palm Springs, California
Research Site
Roseville, California
Research Site
San Diego, California
Research Site
San Pedro, California
Research Site
Tarzana, California
Research Site
Torrance, California
Research Site
Valley Village, California
Research Site
Aurora, Colorado
Research Site
Colorado Springs, Colorado
Research Site
Denver, Colorado
Research Site
Littleton, Colorado
Research Site
Boynton Beach, Florida
Research Site
Clearwater, Florida
Research Site
Crystal River, Florida
Research Site
Daytona Beach, Florida
Research Site
Hollywood, Florida
Research Site
Hollywood, Florida
Research Site
Jacksonville, Florida
Research Site
Largo, Florida
Research Site
Miami, Florida
Research Site
New Port Richey, Florida
Research Site
Pensacola, Florida
Research Site
Ponte Vedra Beach, Florida
Research Site
Port Charlotte, Florida
Research Site
Sarasota, Florida
Research Site
Sarasota, Florida
Research Site
St. Petersburg, Florida
Research Site
Athens, Georgia
Research Site
Atlanta, Georgia
Research Site
Augusta, Georgia
Research Site
Dunwoody, Georgia
Research Site
Gainesville, Georgia
Research Site
Savannah, Georgia
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.